Studies have found that some cancer cell subsets can affect patients’ responses to immunotherapy, which are closely in contact with cancer-associated fibroblasts (CAFs) and CD8+ T cells (CD8Ts) [27, 28]. The gene discussed is CD8A; the disease is cancer.